[go: up one dir, main page]

BR0313091A - Sistema de liberação transdérmica aperfeiçoado para a administração de rotigotina - Google Patents

Sistema de liberação transdérmica aperfeiçoado para a administração de rotigotina

Info

Publication number
BR0313091A
BR0313091A BR0313091-6A BR0313091A BR0313091A BR 0313091 A BR0313091 A BR 0313091A BR 0313091 A BR0313091 A BR 0313091A BR 0313091 A BR0313091 A BR 0313091A
Authority
BR
Brazil
Prior art keywords
rotigotine
matrix
delivery system
tds
transdermal delivery
Prior art date
Application number
BR0313091-6A
Other languages
English (en)
Inventor
Mike Hannay
Dietrich Wilhelm Schacht
Hans-Michael Wolff
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of BR0313091A publication Critical patent/BR0313091A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"SISTEMA DE LIBERAçãO TRANSDéRMICA APERFEIçOADO PARA A ADMINISTRAçãO DE ROTIGOTINA". é provido um Sistema de Liberação Transdérmica (TDS) aperfeiçoado compreendendo uma camada de fundo inerte aos componentes da matriz, uma matriz auto-adesiva contendo rotigotina e uma lâmina ou folha protetora a ser removida antes da utilização, caracterizado pelo fato da matriz auto-adesiva consistir de um polímero semi-permeável sólido ou semi-sólido (1) em que foi incorporada rotigotina em sua forma de base livre, (2) que é saturado com rotigotina e contém a dita rotigotina como uma pluralidade de micro-reservatórios no interior da matriz, (3) que é altamente permeável à base livre da rotigotina, (4) que é impermeável à forma protonada da rotigotina, (5) em que o diâmetro máximo dos micro-reservatórios é menor que a espessura da matriz. O dito TDS provê um fluxo aumentado de rotigotina através da interface TDS/pele.
BR0313091-6A 2002-07-30 2003-07-28 Sistema de liberação transdérmica aperfeiçoado para a administração de rotigotina BR0313091A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02016860A EP1386605A1 (en) 2002-07-30 2002-07-30 Improved transdermal delivery system for the administration of rotigotine
PCT/EP2003/008320 WO2004012730A1 (en) 2002-07-30 2003-07-28 Improved transdermal delivery system for the administration of rotigotine

Publications (1)

Publication Number Publication Date
BR0313091A true BR0313091A (pt) 2005-06-21

Family

ID=30011090

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0313091-6A BR0313091A (pt) 2002-07-30 2003-07-28 Sistema de liberação transdérmica aperfeiçoado para a administração de rotigotina

Country Status (19)

Country Link
EP (2) EP1386605A1 (pt)
JP (2) JP4837916B2 (pt)
KR (1) KR101016838B1 (pt)
CN (2) CN101953819A (pt)
AT (1) ATE322263T1 (pt)
AU (1) AU2003258539B2 (pt)
BR (1) BR0313091A (pt)
CA (1) CA2491366A1 (pt)
DE (1) DE60304477T2 (pt)
DK (1) DK1524975T3 (pt)
ES (1) ES2256780T3 (pt)
IL (1) IL165918A0 (pt)
MX (1) MXPA05000350A (pt)
NO (1) NO333297B1 (pt)
PL (1) PL217079B1 (pt)
PT (1) PT1524975E (pt)
SI (1) SI1524975T1 (pt)
WO (1) WO2004012730A1 (pt)
ZA (1) ZA200500252B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
DE10361259A1 (de) * 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von Rotigotine in einem Frühstadium von Morbus Parkinson zur Prävention des weiteren Neuronenverlustes
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
WO2006039532A2 (en) * 2004-09-29 2006-04-13 Schwarz Pharma, Inc. Transdermal therapeutic system for parkinson’s disease
US7353034B2 (en) 2005-04-04 2008-04-01 X One, Inc. Location sharing and tracking using mobile phones or other wireless devices
EP2742934A1 (en) * 2008-10-06 2014-06-18 Mylan Technologies, Inc. Amorphous rotigotine transdermal system
DE102008060203A1 (de) 2008-12-07 2010-06-10 Dietrich Wilhelm Schacht Wirkstoffstabilisierende flächenförmige Vorrichtung
EP2201941A1 (de) 2008-12-29 2010-06-30 UCB Pharma GmbH Pflaster-Herstellungstechnologie
PL3257504T3 (pl) * 2009-12-22 2024-10-21 UCB Biopharma SRL Poliwinylopirolidon do stabilizacji stałej dyspersji niekrystalicznej postaci rotygotyny
CA2793571C (en) 2010-04-30 2015-10-13 Teikoku Pharma Usa, Inc. Propynylaminoindan transdermal compositions
WO2012129429A2 (en) 2011-03-24 2012-09-27 Teikoku Pharma Usa, Inc. Transdermal compositions comprising an active agent layer and an active agent conversion layer
EP2559435A1 (en) 2011-08-19 2013-02-20 UCB Pharma GmbH Rotigotine in the treatment of hemispatial neglect, stroke and deficits following stroke
US9913812B2 (en) 2011-11-09 2018-03-13 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
DE102011119043A1 (de) 2011-11-22 2013-05-23 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Transdermales therapeutisches System (TDS) mit Rotigotin
DE102011090178A1 (de) 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
AU2013285733B2 (en) * 2012-07-05 2016-11-10 Sk Chemicals Co., Ltd. Transdermally absorbable preparation containing rotigotine
KR101856515B1 (ko) 2012-11-02 2018-05-10 테이코쿠 팔마 유에스에이, 인코포레이티드 프로피닐아미노인단 경피 조성물
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
JP2016135744A (ja) * 2013-05-08 2016-07-28 株式会社 ケイ・エム トランスダーム 貼付剤
WO2014198422A1 (de) 2013-06-14 2014-12-18 Tesa Labtec Gmbh Transdermales therapiesystem (tts) mit rotigotin
WO2014198423A1 (de) 2013-06-14 2014-12-18 Tesa Labtec Gmbh Dreischichtiges transdermales therapiesystem (tts)
ES2694662T3 (es) 2013-07-03 2018-12-26 Lts Lohmann Therapie-Systeme Ag Sistema terapéutico transdérmico con componente electrónico
CN106456568B (zh) 2014-05-20 2020-03-27 Lts勒曼治疗系统股份公司 包含界面调节剂的经皮递送系统
CN106456567A (zh) * 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
EP3145502B1 (en) * 2014-05-20 2022-07-06 LTS Lohmann Therapie-Systeme AG Transdermal delivery system containing rotigotine
KR102364378B1 (ko) * 2014-05-21 2022-02-16 에스케이케미칼 주식회사 안정성을 향상시킨 로티고틴 함유 경피흡수제제
CN104382850B (zh) * 2014-10-17 2017-12-22 烟台大学 一种罗替戈汀微乳及微乳凝胶
WO2019234662A1 (en) * 2018-06-07 2019-12-12 Nal Pharmaceutical Group Limited Transdermal drug delivery system containing rotigotine
DK3854388T3 (da) 2020-01-24 2023-11-27 Luye Pharma Switzerland Ag Transdermalt terapeutisk system omfattende rotigotin og mindst et ikke-aminresistent silikoneklæbestof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
DE19940238A1 (de) * 1999-08-25 2001-03-01 Lohmann Therapie Syst Lts Wirkstoffhaltiges therapeutisches System zur Applikation auf der Haut mit mindestens zwei polymerhaltigen Schichten
EP1256340B1 (en) * 2001-05-08 2003-08-13 Schwarz Pharma Ag Improved transdermal therapeutic system for the treatment of Parkinson's disease
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
EP1386604A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system

Also Published As

Publication number Publication date
JP2011219485A (ja) 2011-11-04
KR20050056942A (ko) 2005-06-16
PL374814A1 (en) 2005-10-31
CN101953819A (zh) 2011-01-26
JP4837916B2 (ja) 2011-12-14
DK1524975T3 (da) 2006-07-31
NO333297B1 (no) 2013-04-29
EP1524975B9 (en) 2012-02-22
JP5564469B2 (ja) 2014-07-30
DE60304477D1 (de) 2006-05-18
AU2003258539A1 (en) 2004-02-23
PL217079B1 (pl) 2014-06-30
IL165918A0 (en) 2006-01-15
EP1524975B1 (en) 2006-04-05
EP1386605A1 (en) 2004-02-04
ATE322263T1 (de) 2006-04-15
NO20050472L (no) 2005-01-27
WO2004012730A1 (en) 2004-02-12
PT1524975E (pt) 2006-07-31
AU2003258539B2 (en) 2008-08-21
KR101016838B1 (ko) 2011-02-22
CA2491366A1 (en) 2004-02-12
CN1671375A (zh) 2005-09-21
MXPA05000350A (es) 2005-03-31
ES2256780T3 (es) 2006-07-16
ZA200500252B (en) 2006-01-25
SI1524975T1 (sl) 2006-06-30
JP2005535687A (ja) 2005-11-24
DE60304477T2 (de) 2006-12-14
EP1524975A1 (en) 2005-04-27

Similar Documents

Publication Publication Date Title
BR0313091A (pt) Sistema de liberação transdérmica aperfeiçoado para a administração de rotigotina
ATE343380T1 (de) Verbessertes transdermales abgabesystem
MXPA04001676A (es) Sistema terapeutico transdermico con fentanilo o sustancias relacionadas.
WO2004060447A3 (en) Transdermal delivery using encapsulated agent activated by ultrasound and/or heat
ATE526038T1 (de) Implantierbares medizinprodukt mit kontinuierlichem mittel-konzentrationsgefälle
AR093940A1 (es) Sistema de liberacion transdermica, metodo de preparacion
NZ541807A (en) UV stable transdermal therapeutic plaster
AR050621A1 (es) Sistema terapeutico transdermal con una capa adherente procedimiento para el siliconado de una capa de respaldo y empleo de la capa de respaldo
WO2001068060A3 (de) Stabilisierte übersättigte transdermale therapeutische matrixsysteme
ATE396714T1 (de) Transdermales therapeutisches system mit verbessertem langzeittragekomfort
DK0474647T3 (da) Fremgangsmåde og indretning til frigivelse af lægemidler til huden
CA2387143A1 (en) Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin
MX2009008993A (es) Dispositivo para la administracion percutanea de bisoprolol.
WO2016149077A3 (en) Fentanyl transdermal delivery system
DK1143938T3 (da) Transdermalt terapeutisk system med en selvklæbende matrix, der indeholder organiske syreadditionssalte af alkaloider af morphin- eller morphin-type
DK0379933T3 (da) Superficielt behandlingssystem med indhold af et antineoplastisk aktivstof, især 5-fluoruracil
MXPA05008366A (es) Sistema terapeutico transdermico adecuado para la aplicacion de calor para promover la penetracion de sustancias activas y el uso del mismo.
MY110391A (en) Nitroglycerin-containing patch, a process for the production and the use thereof
ATE214606T1 (de) Transdermales therapeutisches system mit dem wirkstoff scopolaminbase
TW200719902A (en) Solid transdermal therapeutic system with uv absorber
DE20221159U1 (de) Transdermales therapeutisches System mit Fentanyl bzw. verwandten Substanzen

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/38, A61K 9/70, A61P 25/16

Ipc: A61K 31/38 (2011.01), A61K 9/70 (2011.01), A61P 25

B25D Requested change of name of applicant approved

Owner name: UCB PHARMA GMBH (DE)

Free format text: NOME ALTERADO DE: SCHWARZ PHARMA AG

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE. PAGAR RESTAURACAO.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2259 DE 22/04/2014.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements